SCHEMBL10101799

SCHEMBL10101799

COC(=O)c1c(C)cncc1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
LMNA P02545 2/20 0.47
RAB9A P51151 1/20 0.47
HPGD P15428 1/20 0.47
AOC3 Q16853 1/20 0.45
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
BRD4 O60885 1/20 0.45
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
LIPE Q05469 1/20 0.43
LRRK2 Q5S007 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15373873 0.88 AOC3 (0.44) MAPTL3MBTL1AOC3RXRARXRB
SCHEMBL112286 0.87 P4HTM (0.44) MAPTL3MBTL1RAB9AAOC3RXRA
SCHEMBL10101806 0.85 EGFR (0.51) MAPTLMNAHPGDAOC3RXRA
SCHEMBL9724299 0.79 HPGD (0.56) MAPTL3MBTL1LMNARAB9AHPGD
SCHEMBL10101802 0.79 MAPT (0.45) MAPTL3MBTL1LMNARAB9AHPGD
SCHEMBL25541338 0.77 TDP1 (0.55) MAPTL3MBTL1LMNARAB9AHPGD
SCHEMBL15065246 0.77 PARP10 (0.51) AOC3RXRABRD4SGMS2P4HTM
SCHEMBL27870706 0.77 LMNA (0.48) MAPTL3MBTL1LMNARAB9AHPGD
SCHEMBL23022116 0.77 SGMS2 (0.52) L3MBTL1LMNAHPGDLRRK2ALDH1A1
SCHEMBL7214874 0.76 L3MBTL1 (0.58) MAPTL3MBTL1AOC3RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828988-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-8367654-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20120108569-A1 8-AZA Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108569-A1 8-AZA Tetracycline Compounds TET1, TET3, HDAC8 MAPT 921/4885L3MBTL1 4756/4885LMNA 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.